S&P 500   3,840.41 (-0.77%)
DOW   31,343.03 (-0.15%)
QQQ   314.70 (-1.16%)
AAPL   124.01 (-0.89%)
MSFT   230.95 (-1.25%)
FB   257.22 (-0.69%)
GOOGL   2,044.73 (-0.96%)
TSLA   688.62 (+0.32%)
AMZN   3,054.78 (-1.28%)
NVDA   525.16 (-2.07%)
BABA   236.13 (+0.73%)
CGC   34.56 (-1.96%)
GE   13.33 (+2.70%)
MU   92.67 (+1.73%)
NIO   44.06 (+1.78%)
AMD   83.18 (-1.13%)
T   28.34 (+0.43%)
F   12.26 (-2.31%)
ACB   10.83 (-1.81%)
DIS   195.01 (+0.55%)
BA   229.86 (+3.01%)
NFLX   530.42 (-3.18%)
PFE   33.59 (+0.24%)
S&P 500   3,840.41 (-0.77%)
DOW   31,343.03 (-0.15%)
QQQ   314.70 (-1.16%)
AAPL   124.01 (-0.89%)
MSFT   230.95 (-1.25%)
FB   257.22 (-0.69%)
GOOGL   2,044.73 (-0.96%)
TSLA   688.62 (+0.32%)
AMZN   3,054.78 (-1.28%)
NVDA   525.16 (-2.07%)
BABA   236.13 (+0.73%)
CGC   34.56 (-1.96%)
GE   13.33 (+2.70%)
MU   92.67 (+1.73%)
NIO   44.06 (+1.78%)
AMD   83.18 (-1.13%)
T   28.34 (+0.43%)
F   12.26 (-2.31%)
ACB   10.83 (-1.81%)
DIS   195.01 (+0.55%)
BA   229.86 (+3.01%)
NFLX   530.42 (-3.18%)
PFE   33.59 (+0.24%)
S&P 500   3,840.41 (-0.77%)
DOW   31,343.03 (-0.15%)
QQQ   314.70 (-1.16%)
AAPL   124.01 (-0.89%)
MSFT   230.95 (-1.25%)
FB   257.22 (-0.69%)
GOOGL   2,044.73 (-0.96%)
TSLA   688.62 (+0.32%)
AMZN   3,054.78 (-1.28%)
NVDA   525.16 (-2.07%)
BABA   236.13 (+0.73%)
CGC   34.56 (-1.96%)
GE   13.33 (+2.70%)
MU   92.67 (+1.73%)
NIO   44.06 (+1.78%)
AMD   83.18 (-1.13%)
T   28.34 (+0.43%)
F   12.26 (-2.31%)
ACB   10.83 (-1.81%)
DIS   195.01 (+0.55%)
BA   229.86 (+3.01%)
NFLX   530.42 (-3.18%)
PFE   33.59 (+0.24%)
S&P 500   3,840.41 (-0.77%)
DOW   31,343.03 (-0.15%)
QQQ   314.70 (-1.16%)
AAPL   124.01 (-0.89%)
MSFT   230.95 (-1.25%)
FB   257.22 (-0.69%)
GOOGL   2,044.73 (-0.96%)
TSLA   688.62 (+0.32%)
AMZN   3,054.78 (-1.28%)
NVDA   525.16 (-2.07%)
BABA   236.13 (+0.73%)
CGC   34.56 (-1.96%)
GE   13.33 (+2.70%)
MU   92.67 (+1.73%)
NIO   44.06 (+1.78%)
AMD   83.18 (-1.13%)
T   28.34 (+0.43%)
F   12.26 (-2.31%)
ACB   10.83 (-1.81%)
DIS   195.01 (+0.55%)
BA   229.86 (+3.01%)
NFLX   530.42 (-3.18%)
PFE   33.59 (+0.24%)
Log in
NASDAQ:ASND

Ascendis Pharma A/S Stock Forecast, Price & News

$153.31
-1.82 (-1.17 %)
(As of 03/3/2021 09:56 AM ET)
Add
Compare
Today's Range
$152.05
Now: $153.31
$154.00
50-Day Range
$149.17
MA: $156.93
$173.33
52-Week Range
$92.00
Now: $153.31
$183.98
Volume1,722 shs
Average Volume183,174 shs
Market Capitalization$8.19 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.77
Ascendis Pharma A/S, a biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon growth hormone, which has completed Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone which is in Phase II clinical study for treating hypoparathyroidism; and TransCon CNP, a long-acting prodrug of C-type natriuretic peptide which is in Phase II clinical for the treatment of achondroplasia. It is also developing preclinical studies in the field of oncology for potential product candidates and evaluate systemic and localized delivery systems using its TransCon technologies. It also has strategic collaborations with Sanofi to develop TransCon technologies for the treatment of diabetes. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Ascendis Pharma A/S logo

Headlines

Ascendis Pharma A/S Announces Planned Board Transition
December 14, 2020 |  finance.yahoo.com
Ascendis Pharma: TransCon Platform Is A Major Value Driver
November 17, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ASND
CUSIPN/A
Phone45-7022-2244
Employees330
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$14.98 million
Book Value$15.87 per share

Profitability

Net Income$-244,180,000.00
Net Margins-4,042.79%

Miscellaneous

Market Cap$8.19 billion
Next Earnings Date4/7/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.31 out of 5 stars

Medical Sector

703rd out of 1,969 stocks

Pharmaceutical Preparations Industry

346th out of 772 stocks

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$153.31
-1.82 (-1.17 %)
(As of 03/3/2021 09:56 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ASND News and Ratings via Email

Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions

Is Ascendis Pharma A/S a buy right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last twelve months. There are currently 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Ascendis Pharma A/S stock.
View analyst ratings for Ascendis Pharma A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Ascendis Pharma A/S?

Wall Street analysts have given Ascendis Pharma A/S a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Ascendis Pharma A/S wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Ascendis Pharma A/S's next earnings date?

Ascendis Pharma A/S is scheduled to release its next quarterly earnings announcement on Wednesday, April 7th 2021.
View our earnings forecast for Ascendis Pharma A/S
.

How were Ascendis Pharma A/S's earnings last quarter?

Ascendis Pharma A/S (NASDAQ:ASND) issued its earnings results on Monday, November, 16th. The biotechnology company reported ($2.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($1.57) by $0.74. The biotechnology company had revenue of $3.22 million for the quarter, compared to analysts' expectations of $1.94 million. Ascendis Pharma A/S had a negative net margin of 4,042.79% and a negative trailing twelve-month return on equity of 55.72%.
View Ascendis Pharma A/S's earnings history
.

How has Ascendis Pharma A/S's stock been impacted by Coronavirus (COVID-19)?

Ascendis Pharma A/S's stock was trading at $118.53 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ASND shares have increased by 30.9% and is now trading at $155.13.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ASND?

13 Wall Street analysts have issued 12 month price targets for Ascendis Pharma A/S's shares. Their forecasts range from $145.00 to $216.00. On average, they anticipate Ascendis Pharma A/S's share price to reach $183.00 in the next year. This suggests a possible upside of 18.0% from the stock's current price.
View analysts' price targets for Ascendis Pharma A/S
or view top-rated stocks among Wall Street analysts.

Who are Ascendis Pharma A/S's key executives?

Ascendis Pharma A/S's management team includes the following people:
  • Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 50)
  • Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 61)
  • Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 47)
  • Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 52)
  • Ms. Lotte Sønderbjerg, Chief Admin. Officer & Sr. VP (Age 60)
  • Mr. Ami Knoefler, Head of Global Communications
  • Mr. Flemming Steen Jensen, Sr. VP of Product Supply (Age 60)
  • Dr. Kennett Sprogøe, Sr. VP and Head of Innovation & Research (Age 42)
  • Dr. Juha Punnonen M.D., Ph.D., Sr. VP & Head of Oncology (Age 55)
  • Dr. Jens Sigurd Okkels, Sr. VP of Product Devel. (Age 60)

Who are some of Ascendis Pharma A/S's key competitors?

What other stocks do shareholders of Ascendis Pharma A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include AbbVie (ABBV), Alexion Pharmaceuticals (ALXN), Neurocrine Biosciences (NBIX), ACADIA Pharmaceuticals (ACAD), BioMarin Pharmaceutical (bmrn), Gilead Sciences (GILD), Incyte (INCY), Exelixis (EXEL), GW Pharmaceuticals (GWPH) and NVIDIA (NVDA).

When did Ascendis Pharma A/S IPO?

(ASND) raised $85 million in an initial public offering on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager.

What is Ascendis Pharma A/S's stock symbol?

Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND."

Who are Ascendis Pharma A/S's major shareholders?

Ascendis Pharma A/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (12.39%), Artisan Partners Limited Partnership (10.80%), FMR LLC (10.00%), Janus Henderson Group PLC (5.63%), Lone Pine Capital LLC (1.67%) and Victory Capital Management Inc. (0.95%).

Which major investors are selling Ascendis Pharma A/S stock?

ASND stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Price T Rowe Associates Inc. MD, Candriam Luxembourg S.C.A., Ghost Tree Capital LLC, Lakewood Capital Management LP, New York State Common Retirement Fund, Alliancebernstein L.P., and Westpac Banking Corp.

Which major investors are buying Ascendis Pharma A/S stock?

ASND stock was bought by a variety of institutional investors in the last quarter, including Lone Pine Capital LLC, Artisan Partners Limited Partnership, Victory Capital Management Inc., FIL Ltd, FMR LLC, Morgan Stanley, Baillie Gifford & Co., and Janus Henderson Group PLC.

How do I buy shares of Ascendis Pharma A/S?

Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ascendis Pharma A/S's stock price today?

One share of ASND stock can currently be purchased for approximately $155.13.

How much money does Ascendis Pharma A/S make?

Ascendis Pharma A/S has a market capitalization of $8.29 billion and generates $14.98 million in revenue each year. The biotechnology company earns $-244,180,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis.

How many employees does Ascendis Pharma A/S have?

Ascendis Pharma A/S employs 330 workers across the globe.

What is Ascendis Pharma A/S's official website?

The official website for Ascendis Pharma A/S is www.ascendispharma.com.

Where are Ascendis Pharma A/S's headquarters?

Ascendis Pharma A/S is headquartered at TUBORG BOULEVARD 12, HELLERUP G7, DK-2900.

How can I contact Ascendis Pharma A/S?

Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.